|
|
|
|
|
Dexrazoxane
drug data and news
Dexrazoxane drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Dexrazoxane | ||
| Brand Names/Synonyms | ADR-529; CCRIS 1271; Cardioxane; Desrazoxane; Dexrazoxane; Dexrazoxane [Usan:Ban:Inn]; Dexrazoxano [Inn-Spanish]; Dexrazoxanum [Inn-Latin]; Dextrorazoxane; Dyzoxane; Eucardion; ICRF 159; ICRF-159; ICRF-187; Razoxana [Inn-Spanish]; Razoxane; Razoxane [Ban:Inn]; Razoxanum [Inn-Latin]; Razoxin; Tepirone; Troxozone; Zinecard | ||
| Indication | For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose. | ||
| Mechanism Of Action | The mechanism by which Dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that Dexrazoxane is converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. | ||
| Dexrazoxane News (When available) |
| ||
| Dosage Forms | LIQUID;POWDER FOR SOLUTION | ||
| Drug_Category | Immunosuppressive Agents; Chelating Agents; Cardiovascular Agents; Antineoplastic Agents; ATC:V03AF02 | ||
| Absorption | IV administration results in complete bioavailability. | ||
| Interactions |
Interactions for Dexrazoxane: ZINECARD does not influence the pharmacokinetics of doxorubicin. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term carcinogenicity studies have been carried out with dexrazoxane in animals. Dexrazoxane was not mutagenic in the Ames test but was found to be clastogenic to human lymphocytes in vitro and to mouse bone marrow erythrocytes in vivo (micronucleus test). The possible adverse effects of ZINECARD on the fertility of humans and experimental animals, male or female, have not been adequately studied. Testicular atrophy was seen with dexrazoxane administration at doses as low as 30 mg/kg weekly for 6 weeks in rats (1/3 the human dose on a mg/m 2 basis) and as low as 20 mg/kg weekly for 13 weeks in dogs (approximately equal to the human dose on a mg/m 2 basis). | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 4-[2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione | ||
| Chemical Formula | C11H16N4O4 | ||
| Molecular Weight | 268.269 g/mol | ||
| Smiles String | CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2 | ||
| Melting Point | 191 - 197 °C | ||
| Water Solubility | Sparingly soluble | ||
| State | Solid | ||
| LogP/Hphobicity | -2.135 | ||
| Isoelectric Point | 2.1 | ||
| Biotransformation | Dexrazoxane is hydrolysed by the enzyme dihydropyrimidine amidohydrolase in the liver and kidney to active metabolites that are capable of binding to metal ions. | ||
| Half Life | 2.5 hours | ||
| Protein Binding [%] | Very low (< 2%) | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Dexrazoxane.html http://www.rxlist.com/cgi/generic2/dexrazoxane.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00090 | ||
| CAS Registry Number | 24584-09-6 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:213617 | ||
| PharmGKB ID | PA449259 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2153440 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |